Apricot Capital

Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics. Founded in 2015, Apricot Capital consists of more than 20 professionals and consultants with experience in the healthcare industry. Its professional background includes life sciences, medicine, finance and law.

Haigang Chen

Managing Partner

39 past transactions

Shenqi Medical

Private Placement in 2020
Shanghai Shenqi Medical Technology Co., Ltd. engages in the research and development, production, and sale of minimally invasive vascular interventional products. The company offers releasable embolization systems, peripheral microcatheters, distal access guide catheters, drug-coated coronary balloon catheters, and left atrial appendage occluder systems. It offers its products for cardiovascular intervention, peripheral vascular intervention, neurovascular intervention, and structural heart diseases. The company was founded in 2014 and is based in Shanghai, China.

Jiuxin Medical

Series A in 2019
Jiuxin Medical is a medical company that provides pre-hospital first-aid products and solutions for cardiovascular fields. The company was founded by a group of like-minded people who have mastered the industry's leading expertise and operational experience. The company has been approved for dozens of invention patents, and the products developed have complete independent intellectual property rights.

Jiuxin Medical

Series A in 2019
Jiuxin Medical is a medical company that provides pre-hospital first-aid products and solutions for cardiovascular fields. The company was founded by a group of like-minded people who have mastered the industry's leading expertise and operational experience. The company has been approved for dozens of invention patents, and the products developed have complete independent intellectual property rights.

Akeso, Inc.

Private Placement in 2019
Akeso, Inc. (HKEX Code: 9926.HK) is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. The Company dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. Akeso’s vision is to become a global leader in developing, manufacturing and commercializing innovative, next-generation and affordable therapeutic antibodies for patients worldwide.

Yituo Medical

Private Placement in 2020
Yituo Medical is headquartered in China.

Tavotek Biotherapeutics

Series A in 2019
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Our company management and advisors consist of veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for biologics: TavoSelect (an innovative Phage Display Library), TavoPrecise (engineering platform for tissue-specific biologics), and TavoMIP (a multicyclic peptide platform). Along with these platforms, Tavotek has a rich and diverse pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases.

Forerunner Medical

Private Placement in 2020
Forerunner Medical (Shanghai) Co., Ltd. develops and manufactures medical devices for minimally invasive treatment. It primarily develops and produces low-temperature plasma radiofrequency generators and electrodes for sport medicine, disk demo-pression, and ENT treatment applications. Its products include plasma radiofrequency systems; and electrodes for joint, spine, cervical, lumbar, transforaminal endoscopic operation, and ENT treatment applications. The company was founded in 2009 and is based in Shanghai, China.

Immvira

Series B in 2020
IMMVIRA CO.,LTD, a biopharmaceutical company, develops a range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents. The company's product lines include oHSV encoding IL12 and anti-PD-1Ab (T3) to be administered by direct injection into the tumor mass; oHSV encoding IL12 only (T2) for use in combination with immune-modulators administered systemically; auxiliary therapies; and genetically engineered oHSV to infect tumor cells bearing unique receptors on their surface. IMMVIRA CO.,LTD was founded in 2015 and is based in Shenzhen, China.

Genskey

Series C in 2020
GensKey is a genetic testing medical diagnostic service provider that applies high-throughput sequencing technology to pathogen diagnosis to solve a series of difficulties in the detection rate, timeliness and accuracy of pathogenic diagnosis, so that many patients with severe infections get timely and accurate. Diagnosis.

Etern

Series B in 2021
Etern is developing small molecule innovative drugs for oncology therapies.

Jabrehoo Med Tech

Series B in 2020
Jabrehoo focusing on clinical transformation and innovative research and development of related products in the field of assisted reproduction, genetics and eugenics, providing one-stop solutions for reproductive genetics for assisted reproduction couples, infertile patients, and people who are preparing for pregnancy, and promoting the localization of various detections.

Beijing Runlong Medical Technology Co., Ltd.

Private Placement in 2020
Runlong Medical Technology Co., Ltd develops and manufactures medical orthopedics and sports medicine devices. It offers consumables, power systems, surgical tools with planers, anchors with wire, titanium plates with loops, and other products applied in sports medicine hospitals in China. The company was founded in 2013 and is based in Beijing, China.

GRIT Biotechnology

Series A in 2021
GRIT Biotechnology is engaged in research and development of tumor infiltration lymphocytes immunotherapy for curing solid tumors. The company is based in Shanghai, China.

Yachuang Medical

Private Placement in 2019
Yachuang Medical manufactures pharmaceuticals. The company was founded in 2016 and is based in Shanghai, China.

Beijing Jiushi Shenkang Medical Technology Co., Ltd.

Private Placement in 2020
Beijing Jiushi Shenkang Medical Technology Co., Ltd. engages in the research, development, production, and sale of implantable medical devices. The company was founded in 2016 and is based in Beijing, China.

Immvira

Private Placement in 2020
IMMVIRA CO.,LTD, a biopharmaceutical company, develops a range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents. The company's product lines include oHSV encoding IL12 and anti-PD-1Ab (T3) to be administered by direct injection into the tumor mass; oHSV encoding IL12 only (T2) for use in combination with immune-modulators administered systemically; auxiliary therapies; and genetically engineered oHSV to infect tumor cells bearing unique receptors on their surface. IMMVIRA CO.,LTD was founded in 2015 and is based in Shenzhen, China.

Simcere Pharma

Post in 2024
Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.

Axiata

Series A in 2022
Axiata is a technological business that combines product creation, research, and sales of lab supplies. The company enables in vitro diagnostic reagent producers, pharmaceutical firms, and biological preparation businesses to build value by offering them effective services and products. The company continues to work in harmony with clients while providing goods that satisfy consumer demand. Customers can purchase products and OEM services from them.

Genskey

Private Placement in 2020
GensKey is a genetic testing medical diagnostic service provider that applies high-throughput sequencing technology to pathogen diagnosis to solve a series of difficulties in the detection rate, timeliness and accuracy of pathogenic diagnosis, so that many patients with severe infections get timely and accurate. Diagnosis.

Esonant Medical Technology Co., Ltd.

Private Placement in 2020
Esonant Medical Technology Co., Ltd. is a developer of active surgical equipment. The company is based in Kunshan, China.
Jousing Medical Technology (Suzhou) Co., Ltd. manufactures pre-hospital products and solutions for cardiovascular fields. The company is based in Suzhou, China.

Jabrehoo Med Tech

Private Placement in 2020
Jabrehoo focusing on clinical transformation and innovative research and development of related products in the field of assisted reproduction, genetics and eugenics, providing one-stop solutions for reproductive genetics for assisted reproduction couples, infertile patients, and people who are preparing for pregnancy, and promoting the localization of various detections.

Medilink Therapeutics

Series A in 2021
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Analytical BioSciences Limited

Private Placement in 2020
Analytical BioSciences Limited engages in single-cell genome research. The company, in partnership with medical research institutions, hospitals, and pharmaceutical companies, applies single cell genomics and bioinformatics in the diagnosis and treatment of human diseases. Analytical BioSciences Limited was founded in 2018 and is based in Beijing, China.

SinoMab Bioscience

Venture Round in 2019
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a BTK inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, NHL, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China and Hong Kong. SinoMab BioScience Limited was founded in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Jiuxin Medical Technology

Private Placement in 2019
Jiuxin Medical Technology Co., Ltd. researches, manufactures, and markets medical, transport, and emergency ventilators. It offers medical ventilators, which are used in operating rooms, intensive care units, ambulances, first-aid, and transportation within hospitals; and portable, home-care, and critical-care ventilators. The company also offers steel and aluminum alloy oxygen cylinders; and accessories, such as manual resuscitations, oxygen inhalers, breathe circuits, splint and tank lung simulation products, humidifiers, ventilator support arms, water traps, face masks, and filters. Jiuxin Medical Technology Co., Ltd. was founded in 2000 and is based in Taizhou, China. As of November 12, 2015, Jiuxin Medical Technology Co., Ltd. operates as a subsidiary of Shenzhen Das Intellitech Co., Ltd.

Shenqi Medical

Series C in 2020
Shanghai Shenqi Medical Technology Co., Ltd. engages in the research and development, production, and sale of minimally invasive vascular interventional products. The company offers releasable embolization systems, peripheral microcatheters, distal access guide catheters, drug-coated coronary balloon catheters, and left atrial appendage occluder systems. It offers its products for cardiovascular intervention, peripheral vascular intervention, neurovascular intervention, and structural heart diseases. The company was founded in 2014 and is based in Shanghai, China.

Forerunner Medical

Series B in 2021
Forerunner Medical (Shanghai) Co., Ltd. develops and manufactures medical devices for minimally invasive treatment. It primarily develops and produces low-temperature plasma radiofrequency generators and electrodes for sport medicine, disk demo-pression, and ENT treatment applications. Its products include plasma radiofrequency systems; and electrodes for joint, spine, cervical, lumbar, transforaminal endoscopic operation, and ENT treatment applications. The company was founded in 2009 and is based in Shanghai, China.

D2M Biotherapeutics Limited

Private Placement in 2020
D2M Biotherapeutics Limited researches and develops a genetics-driven target identification platform and tumor immunological drugs. The company engages in discovery, development, and commercialization of therapeutics and therapies against those targets for treatment and prevention of human diseases. The company was incorporated in 2019 and is based in Hong Kong.

Yachuang Medical

Angel Round in 2019
Yachuang Pharmaceuticals is an innovative pharmaceutical research and development company focusing on liver diseases such as NASH and HBV. Founder Dr. Xu has worked in multinational pharmaceutical companies such as Johnson & Johnson, with over 20 years of successful innovation and management of innovative drugs. experience.

SinoMab Bioscience

Private Placement in 2019
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a BTK inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, NHL, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China and Hong Kong. SinoMab BioScience Limited was founded in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Bellen

Private Placement in 2020
Bellen Chemistry is a premier provider of a variety of heterocycles. Our activity is focused on the design and development of novel molecules,6361413375267061158256368.jpgintermediates for the Chemical and Pharmaceutical industries. Bellen Chemistryhas a strong R&D team with a talent pool of 200+ trained scientists. We have excellent track records, as we deliver unrivalled chemical innovation to our customers worldwide.

Qihe Biotech

Seed Round in 2022
Shandong Qihe Biotechnology Co., Ltd. produces, processes, and sells edible mushrooms. The company offers shiitake mushroom spawns, oyster mushroom logs, and oyster mushroom spawn. It engages in research and development of edible fungi products. Shandong Qihe Biotechnology Co., Ltd. was founded in 2000 and is headquartered in Zibo, China.

LinkZill

Seed Round in 2022
LinkZill is a high-tech firm with products such as organic semiconductor materials, thin-film transistors, array, and portable test systems.